x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243102
| Product Information | |
|---|---|
| CAS No. | 408504-26-7 |
| Synonyms | GW-869682X |
| Formula | C23H28O9 |
| Molecular Weight | 448.46 |
| SMILES | COC(C=C1)=CC=C1CC(C=CC=C2)=C2O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)COC(OCC)=O |
| Target | SGLT |
| Product Description | Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes. |
| Format & Storage | |
|---|---|
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
